FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2049679426> ?p ?o ?g. }

• W2049679426 endingPage "246" @default.
• W2049679426 startingPage "237" @default.
• W2049679426 abstract "The binding of camptothecin (CPT) to the DNA-topoisomerase complex is reversible, but it needs to be maintained for maximal inhibitory activity. It is also dependent on the chemical structure of CPT. The lactone form is thought to be necessary for the activity. In human serum, the equilibrium between lactone and carboxylate is in favor of the latter. For these reasons, alternative administration of CPT analogues is being evaluated. The ideal compound would remain in lactone form and would expose the host for long periods of time to its effects. Oral administration of irinotecan (CPT-11) and topotecan (TPT) is discussed by other investigators. We studied oral rubitecan and reported a low lactone to total drug area under the plasma concentration-time curve (AUCP) ratio (14.7%), with low plasma concentration over time despite repeated administrations and the presence of an enterohepatic cycle. Aerosolization of a liposomal formulation of rubitecan is currently under study. Six patients have been treated once a day for 5 days every 3 weeks. The dose was 6.7 micrograms/kg/day. Plasma levels are dose for dose higher than those after oral administration, but the ratio of lactone versus total drug is low. No toxicity was observed. The study will continue with increasing doses and lengths of administration. Intrathecal administration of topotecan has been studied in a phase I trial in children. Doses of 0.4 mg are tolerated without toxicity, and clinical responses have been seen in patients with refractory meningial carcinomatosis. Phase II studies are planned. Intraperitoneal (i.p.) administration of topotecan has been studied in a phase I trial as a 24-hour infusion in 5% dextrose at pH 3.5 every 21 days. Dose-limiting toxicity is 4 mg/m2. Toxic effects are neutropenia, anemia, emesis, fever, and pain. Five of 10 patients with ascites had symptomatic relief. Pharmacokinetic analysis demonstrates a second-order kinetics with elimination half-lives of 0.49 and 2.7 hours. The peritoneal to plasma AUC ratio was 31.2. Intramuscular, transdermal, and subcutaneous administrations have been extensively studied in the mouse." @default.
• W2049679426 created "2016-06-24" @default.
• W2049679426 creator A5010882553 @default.
• W2049679426 creator A5023657472 @default.
• W2049679426 creator A5024300677 @default.
• W2049679426 creator A5062277760 @default.
• W2049679426 creator A5089486616 @default.
• W2049679426 date "2000-12-01" @default.
• W2049679426 modified "2023-09-27" @default.
• W2049679426 title "Alternative Administration of Camptothecin Analogues" @default.
• W2049679426 cites W1493735244 @default.
• W2049679426 cites W1522093588 @default.
• W2049679426 cites W17576097 @default.
• W2049679426 cites W1795993802 @default.
• W2049679426 cites W1963824944 @default.
• W2049679426 cites W1967990903 @default.
• W2049679426 cites W1970179483 @default.
• W2049679426 cites W1972483602 @default.
• W2049679426 cites W1979749400 @default.
• W2049679426 cites W1980071452 @default.
• W2049679426 cites W1980521536 @default.
• W2049679426 cites W1984753317 @default.
• W2049679426 cites W1985186177 @default.
• W2049679426 cites W1991413583 @default.
• W2049679426 cites W1991687965 @default.
• W2049679426 cites W1997361520 @default.
• W2049679426 cites W2012797500 @default.
• W2049679426 cites W2019904371 @default.
• W2049679426 cites W2020157942 @default.
• W2049679426 cites W2035768225 @default.
• W2049679426 cites W2050838429 @default.
• W2049679426 cites W2051041111 @default.
• W2049679426 cites W2056436200 @default.
• W2049679426 cites W2057409012 @default.
• W2049679426 cites W2058114203 @default.
• W2049679426 cites W2059184955 @default.
• W2049679426 cites W2067024881 @default.
• W2049679426 cites W2068478966 @default.
• W2049679426 cites W2070540557 @default.
• W2049679426 cites W2143114341 @default.
• W2049679426 cites W2165351839 @default.
• W2049679426 cites W2301968739 @default.
• W2049679426 cites W30124112 @default.
• W2049679426 doi "https://doi.org/10.1111/j.1749-6632.2000.tb07042.x" @default.
• W2049679426 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11193899" @default.
• W2049679426 hasPublicationYear "2000" @default.
• W2049679426 type Work @default.
• W2049679426 sameAs 2049679426 @default.
• W2049679426 citedByCount "14" @default.
• W2049679426 countsByYear W20496794262014 @default.
• W2049679426 crossrefType "journal-article" @default.
• W2049679426 hasAuthorship W2049679426A5010882553 @default.
• W2049679426 hasAuthorship W2049679426A5023657472 @default.
• W2049679426 hasAuthorship W2049679426A5024300677 @default.
• W2049679426 hasAuthorship W2049679426A5062277760 @default.
• W2049679426 hasAuthorship W2049679426A5089486616 @default.
• W2049679426 hasConcept C108215921 @default.
• W2049679426 hasConcept C112705442 @default.
• W2049679426 hasConcept C121608353 @default.
• W2049679426 hasConcept C126322002 @default.
• W2049679426 hasConcept C147897179 @default.
• W2049679426 hasConcept C158456008 @default.
• W2049679426 hasConcept C185592680 @default.
• W2049679426 hasConcept C202751555 @default.
• W2049679426 hasConcept C2776093070 @default.
• W2049679426 hasConcept C2776612806 @default.
• W2049679426 hasConcept C2776694085 @default.
• W2049679426 hasConcept C2777056448 @default.
• W2049679426 hasConcept C2778620825 @default.
• W2049679426 hasConcept C2779682216 @default.
• W2049679426 hasConcept C2780259306 @default.
• W2049679426 hasConcept C2780508388 @default.
• W2049679426 hasConcept C2781209748 @default.
• W2049679426 hasConcept C29730261 @default.
• W2049679426 hasConcept C526805850 @default.
• W2049679426 hasConcept C552990157 @default.
• W2049679426 hasConcept C55493867 @default.
• W2049679426 hasConcept C62231903 @default.
• W2049679426 hasConcept C71240020 @default.
• W2049679426 hasConcept C71924100 @default.
• W2049679426 hasConcept C73573662 @default.
• W2049679426 hasConcept C98274493 @default.
• W2049679426 hasConceptScore W2049679426C108215921 @default.
• W2049679426 hasConceptScore W2049679426C112705442 @default.
• W2049679426 hasConceptScore W2049679426C121608353 @default.
• W2049679426 hasConceptScore W2049679426C126322002 @default.
• W2049679426 hasConceptScore W2049679426C147897179 @default.
• W2049679426 hasConceptScore W2049679426C158456008 @default.
• W2049679426 hasConceptScore W2049679426C185592680 @default.
• W2049679426 hasConceptScore W2049679426C202751555 @default.
• W2049679426 hasConceptScore W2049679426C2776093070 @default.
• W2049679426 hasConceptScore W2049679426C2776612806 @default.
• W2049679426 hasConceptScore W2049679426C2776694085 @default.
• W2049679426 hasConceptScore W2049679426C2777056448 @default.
• W2049679426 hasConceptScore W2049679426C2778620825 @default.
• W2049679426 hasConceptScore W2049679426C2779682216 @default.
• W2049679426 hasConceptScore W2049679426C2780259306 @default.
• W2049679426 hasConceptScore W2049679426C2780508388 @default.

• next